Professor Wakelee from Stanford, United States, presented the final DFS...
The final analysis of the DESTINY-Lung02 trial, a dose-blinded phase 2...
Dr Iris Dirven, a medical oncologist in training at the University Hospital of...
The VENUS study is a prospective translational single-institution study that...
Ubamatamab is a bispecific antibody targeting MUC16 on ovarian cancer cells and...
This poster presents findings from the Spectrum study, a single-center...
The ENGOT-cx12 inovaTV 301 trial, co-authored by Professor Vergote and by Prof...
In a subgroup population analysis from the DESTINY-Pan Tumor 02 study, the...
The data presented here is from a pre-planned analysis of the Flipper trial,...
This study explores the role of ctDNA in low estrogen receptor (ER) tumours,...